NCT07243067Not yet recruiting
Tumor-Derived Extracellular Vesicles for Noninvasive Molecular Classification of Kidney Cancer
Source: ClinicalTrials.gov · Last updated 27 Feb 2026
Brief summary (registry, in English)
This is a correlative (lab-based) study aiming to identify protein markers in urine extracellular vesicles (EVs) that can be used to develop non-invasive molecular tests for patients with renal cell carcinoma (RCC). Aim 1 will use urine collected previously in biorepository. Aim 2 will prospectively collect blood specimens pre and post nephrectomy.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 300 (estimated)
- First submitted
- 14 Nov 2025
- Start date
- 15 Jul 2026
- Primary completion date
- 30 Apr 2027
- Lead sponsor
- Mayo Clinic
- Diseases
- Kidney cancer, Childhood cancers
- NCT number
- NCT07243067
What you commit to
- Study type: Observational
- Planned participants: 300
- From 15 Jul 2026 to the primary completion date, 30 Apr 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Does not meet inclusion criteria
Who the study is looking for
- Urine sample in existing biorepository
- High-risk renal cell carcinoma (RCC) per American Urological Association (AUA) guidelines
- Scheduled to undergo nephrectomy
Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.